[关键词]
[摘要]
目的 调查南京地区42家医院调脂药的临床使用情况及发展趋势。方法 回顾性对2016-2018年南京市42家医院调脂药的用药频度(DDDs)、应用品种和销售金额进行统计分析。结果 调脂药的销售金额和DDDs逐年增加,复合年均增长率(CAGR)分别为16.06%、15.98%;他汀类始终占据调脂药市场的主导地位,其销售金额和DDDs的构成比分别超过83.30%、79.53%,且增长较快;依折麦布的增长幅度最大,其销售金额和DDDs的CAGR分别为26.76%、27.13%;DDDs排名列前10位的药品中,阿托伐他汀以绝对优势占据调脂药市场的首位,但其构成比逐年降低;瑞舒伐他汀年均增长率最快,达30.98%,与阿托伐他汀的差距逐年减少,2018年二者已基本持平。依折麦布的市场份额增长幅度较大,其DDDs于2017年跃居第3位。结论 南京地区调脂药各类的构成比相对稳定,以阿托伐他汀为代表的"超级他汀"类药占主导地位,且呈越来越集中趋势;新型调脂药为顽固性血脂异常的防治提供新选择,增长幅度较大,虽然价格较高,但前景依然看好;以血脂康为代表的中成药制剂市场份额降低。
[Key word]
[Abstract]
Objective To evaluate the situation, characteristic, and developing trend of the utilization of lipid regulating agents in 42 hospitals of Nanjing area. Methods The utilization of lipid regulating agents in hospitals from 2016 to 2018 were analyzed statistically in respect of varieties, consumption sum, DDDs, etc. Results Consumption sum and DDDs of lipid regulating agents increased year by year, and the CAGR were 16.06% and 15.98%, respectively. Statins always occupied the top position in the market of lipid regulating agents, whose consumption sum and DDDs occupied more than 83.30% and 79.53%. Among top 10 drugs in the list of DDDs, atorvastat occupied the first position of in the market of lipid regulating agents with an absolute advantage, but its constituent ratio decreased year by year. The CAGR of rosuvastatin was 30.98%, which was the highest. The gap between atorvastatin and atorvastatin is decreasing year by year. In 2018, the two were basically flat. Ezeimibe's market share had increased considerably. DDDs of ezeimibe jumped to the third place in 2017. Conclusion The composition ratio of lipid regulating drugs in Nanjing area is relatively stable. The "super statin" drugs represented by atorvastatin are dominant, which is becoming more and more centralized. Novel lipid regulating agents provide new options for the prevention and treatment of refractory dyslipidemia, so its growth rate is large. Although the price is high, but the prospects are still promising. The market share Chinese patent medicine represented by Xuezhikang decreased year by year.
[中图分类号]
[基金项目]